Results 151 to 160 of about 756,852 (217)

A Prospective Clinical Trial of Efgartigimod for New-Onset Generalized Myasthenia Gravis. [PDF]

Curr Neuropharmacol
Ma C, Shen J, Zhu Y, Zhu R.
europepmc   +1 more source

Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China. [PDF]

Front Immunol
Xu Y, Feng L, Zhang M, Zhou J, Xiao H, Ni Y, Wang R, He Y, Jiang Q, Peng J, Chen H, Zhou H, He D, Luo S, Xi J, Song J, Yan C, Lu J, Zhao C.   +18 more
europepmc   +1 more source

Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study. [PDF]

Front Immunol
An X, Zhu L, Huang X, Zhang Z, Zhang Y, Zhang C.   +5 more
europepmc   +1 more source

Cardiopulmonary exercise testing in mild generalized myasthenia gravis: an exploratory pilot feasibility study. [PDF]

Front Physiol
Stascheit F, Lauermann M, Risch L, Mayer F, Hoffmann S, Meisel A, Roecker K, Cassel M.   +7 more
europepmc   +1 more source

Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study. [PDF]

Front Immunol
Rong X, Sun X, Wang L, Qu M, Jiang L, Liu M.   +5 more
europepmc   +1 more source

Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol. [PDF]

Neurol Res Pract
Kohle F, Konen FF, Grittner U, Schulze D, Glaubitz S, Nelke C, Schroeter CB, Huntemann N, Trillenberg P, Großkreutz J, Schoser B, Schubert C, Zschüntzsch J, Schroeter M, Hegelmaier T, Skripuletz T, Sieb JP, Ruck T, Meuth S, Wiendl H, Keller CW, Lünemann JD, Lehnerer S, Meisel A, Stascheit F.   +24 more
europepmc   +1 more source

Low-dose versus standard-dose intravenous immunoglobulin in generalized myasthenia gravis: a prospective single-center cohort study. [PDF]

Front Neurol
Luo H, Dong L, Yang L, Deng Y, Zhang C, Zhang X, Hu L, Wu Z, Yang X, Jiang Q.   +9 more
europepmc   +1 more source

Nipocalimab in the management of generalized myasthenia gravis: a new targeted therapeutic approach. [PDF]

Ann Med Surg (Lond)
Khalid M, Haider E, Khan A, Haider NU.
europepmc   +1 more source

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+). [PDF]

Front Neurol
Meisel A, Antozzi C, Bhavaraju-Sanka R, De Bleecker JL, Huang WY, Jimenez RH, Verhamme FM, Jiang M, Liu L, Korobko D, Kostera-Pruszczyk A, Utsugisawa K, Verschuuren JJGM, Vu T, Wiendl H, Howard JF.   +15 more
europepmc   +1 more source